114 related articles for article (PubMed ID: 31586853)
1. Neut-X can be successfully used as diagnostic and prognostic tool in MDS.
Boquoi A; Barthuber C; Strapatsas J; Kuendgen A; Kobbe G; Fenk R; Gattermann N; Haas R; Germing U
Leuk Res; 2019 Nov; 86():106224. PubMed ID: 31586853
[No Abstract] [Full Text] [Related]
2. The utility of the Sysmex XE-2100 analyzer's NEUT-X and NEUT-Y parameters for detecting neutrophil dysplasia in myelodysplastic syndromes.
Furundarena JR; Araiz M; Uranga M; Sainz MR; Agirre A; Trassorras M; Uresandi N; Montes MC; Argoitia N
Int J Lab Hematol; 2010 Jun; 32(3):360-6. PubMed ID: 19906272
[TBL] [Abstract][Full Text] [Related]
3. Picking up myelodysplastic syndromes and megaloblastic anemias on peripheral blood: use of NEUT-X and NEUT-Y in guiding smear reviews.
Goel S; Sachdev R; Gajendra S; Jha B; Sahni T; Dorwal P; Srivastava C; Tiwari AK; Sood N; Gupta S; Raina V; Vaid AK
Int J Lab Hematol; 2015 Apr; 37(2):e48-51. PubMed ID: 25132616
[No Abstract] [Full Text] [Related]
4. Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.
Le Roux G; Vlad A; Eclache V; Malanquin C; Collon JF; Gantier M; Schillinger F; Peltier JY; Savin B; Letestu R; Baran-Marszak F; Fenaux P; Ajchenbaum-Cymbalista F
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e237-43. PubMed ID: 20670338
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
6. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
[TBL] [Abstract][Full Text] [Related]
7. [The Utility of XE-2 100 Analyzer's NEUT-X and NEUT-Y Parameters for Detecting Neutrophil Dysplasia in Myelodysplastic Syndromes].
Isono S; Okamur A; Iwamoto M; ImaiJunko IMAI ; Nagata K; Akishino T; Okamura A; Kawamoto S; Kono M; Sugimoto T; Saigo K
Rinsho Byori; 2016 Jan; 64(1):21-6. PubMed ID: 27192792
[TBL] [Abstract][Full Text] [Related]
8. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Schemenau J; Baldus S; Anlauf M; Reinecke P; Braunstein S; Blum S; Nachtkamp K; Neukirchen J; Strup C; Aul C; Haas R; Gattermann N; Germing U
Eur J Haematol; 2015 Sep; 95(3):181-9. PubMed ID: 25600827
[TBL] [Abstract][Full Text] [Related]
9. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte ratio--not an independent prognostic factor in patients with the myelodysplastic syndrome.
Akinci S; Silay K; Ulas A; Guney T; Hacibekiroglu T; Basturk A; Akinci MB; Alkan A; Dilek I
Asian Pac J Cancer Prev; 2014; 15(24):10883-5. PubMed ID: 25605195
[TBL] [Abstract][Full Text] [Related]
11. The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance.
Alexandrakis MG; Passam FH; Dambaki K; Passam AM; Nalbanti F; Stathopoulos ES; Kyriakou DS
Eur J Histochem; 2005; 49(1):27-32. PubMed ID: 15823791
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
13. Teaching cases from the Royal Marsden and St Mary's Hospital case 11 dysplastic neutrophils in an African women.
Ozanne C; Bain B; Catovksy D
Leuk Lymphoma; 1996 Apr; 21(3-4):351-2. PubMed ID: 8726420
[No Abstract] [Full Text] [Related]
14. Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome.
Inaba T; Yuki Y; Yuasa S; Fujita N; Yoshitomi K; Kamisako T; Torii K; Okada T; Urasaki Y; Ueda T; Tohyama K
Int J Hematol; 2011 Aug; 94(2):169-177. PubMed ID: 21732036
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
16. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
17. Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Am J Hematol; 2005 Jul; 79(3):243-5. PubMed ID: 15981222
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of laboratory indexes with prognosis in patients with myelodysplastic syndrome].
Li WW; Li Y; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):116-9. PubMed ID: 22391179
[TBL] [Abstract][Full Text] [Related]
19. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
